Patent ID: 11904003
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of ILDSTTIEI (SEQ ID NO: 1), wherein the cancer is non-Hodgkin lymphoma (NHL), ovarian cancer (OC), acute myeloid leukemia (AML), urinary bladder carcinoma (UBC), esophageal cancer (OSCAR), squamous cell non-small cell lung cancer (NSCLCsquam), NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam (NSCLCother), non-small cell lung cancer adenocarcinoma (NSCLCadeno), melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), gastric cancer (GC), gallbladder cancer (GBC), colorectal cancer (CRC), breast cancer (BRCA), uterine endometrial cancer (UEC), renal cell carcinoma (RCC), pancreatic cancer (PACA), gastro-esophageal junction cancer (GEJC), and chronic lymphocytic leukemia (CLL).